Market Overview

Barclays Injects Allergan With An Upgrade, Says Valuation Model Has Improved

Barclays Injects Allergan With An Upgrade, Says Valuation Model Has Improved
Related AGN
Searching For A Treatment: NASH Investigational Drugs With Catalysts This Year
The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ... (GuruFocus)

Allergan plc Ordinary Shares (NYSE: AGN) is down 26 percent over the last six months, but one analyst said there's only upside to its sickly state. The biotech’s trajectory inspired an upgrade from a three-year Hold.

The Rating

Barclays analyst Douglas Tsao upgraded Allergan to a Buy rating and raised the price target from $220 to $230.

The Thesis

Tsao’s confidence in Allergan is driven by lessening concerns around the firm’s legacy pharmaceutical portfolio and expected growth in its aesthetics franchise, he said. 

A Barclays survey of plastic surgeons and dermatologists indicated durability in the aesthetics segment, which is seen to be a key earnings driver. About 44 percent said their patients would not accept Botox alternatives, and 67 percent reported Botox patients to be “very satisfied” with their treatment against Dysport and Xeomin’s rates of 36 percent and 20 percent, respectively. 

Notably, Revance Therapeutics Inc (NASDAQ: RVNC)’s RT-002 was well received but does not hit the market until 2020.

“While we’ve always viewed the strength of Botox’s brand, our survey showed much stronger perceptions around product quality than we anticipated,” Tsao said in a Monday note.

Altogether, the analyst said he found Allergan attractively valued compared to large-cap pharma peers.

“In the past we didn’t think AGN deserved a premium multiple because [it] overvalued legacy pharma assets,” Tsao said. “However, with the proportion of mature assets declining, we think the valuation case has improved.”

Price Action

Allergan shares were up 0.62 percent at $188.13 at the time of publication. 

Related Links:

Analyst Says Negative Allergan Headlines Are Priced In, Upgrades Stock

Imprimis Launches 99-Cent Generic Drug To Compete With Allergan's Restasis

Latest Ratings for AGN

Jan 2019Credit SuisseMaintainsOutperformOutperform
Nov 2018Leerink SwannInitiates Coverage OnOutperform
Oct 2018Credit SuisseMaintainsOutperformOutperform

View More Analyst Ratings for AGN
View the Latest Analyst Ratings

Posted-In: Barclays BOTOXAnalyst Color Upgrades Health Care Price Target Analyst Ratings General Best of Benzinga


Related Articles (AGN + RVNC)

View Comments and Join the Discussion!

Latest Ratings

CNPRBC CapitalUpgrades34.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Earnings Preview For Heartland Financial USA

Earnings Preview For Werner Enterprises